UAE Lung Cancer Therapeutics Market Report 2022 to 2030

UAE Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the UAE Lung Cancer Therapeutics Market will reach a value of $299 Mn from $149 Mn in 2022, growing at a CAGR of 9.1% during 2022-2030. The Lung Cancer Therapeutics Market in UAE is dominated by a few domestic pharmaceutical companies such as Gulf Pharmaceutical Industries, Neopharma, and SITCO. The Lung Cancer Therapeutics Market in UAE is segmented into different types of cancer and different therapy type. Some of the major factors affecting the UAE lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10AEPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Dr. Vishwa Modhia

Buy Now

UAE Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the UAE Lung Cancer Therapeutics market will reach a value of $299 Mn from $149 Mn in 2022, growing at a CAGR of 9.1% during 2022-2030.

United Arab Emirates (UAE) is a high-income, developing country located in the Middle East bordering the Gulf of Oman and the Persian Gulf. Cancer is the third-leading cause of death in the UAE; cancer care in the UAE has grown considerably over the previous 40 years, from a single centre in Al Ain in 1981 to more than 30 cancer centres and clinics around the UAE today, with at least four comprehensive cancer facilities. In both sexes, lung cancer was the third leading cause of cancer mortality. Multiple AI platforms are currently in use in the UAE, mostly to aid in cancer diagnosis in imaging, such as breast and lung cancer screening.

According to the latest WHO data published in 2020 Lung Cancers Deaths in the Arab Emirates reached 185 or 0.95% of total deaths. The age-adjusted Death Rate is 6.32 per 100,000 population ranking Arab Emirates 127^th in the world. UAE's government spends 5.5% of its GDP on healthcare.

UAE Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Precision oncology, defined as tumour molecular profiling to identify targetable changes, is fast evolving and has entered mainstream clinical practice in the UAE. Non-small-cell lung cancer actionable biomarkers are a good example of precision oncology at the time of advanced disease diagnosis, therapy, and progression. Lung cancer treatment is currently poor in the absence of precision oncology and mutation evaluations. The UAE is an excellent regional corporate trading hub. Cancer treatments, including the most recent FDA-approved medications, are widely available in the UAE. The UAE approval procedure is quick, and many pharmaceuticals are approved soon after they are FDA-approved. For example, in the case of sotorasib, a relatively new lung cancer treatment, the UAE was the second country in the world to approve the drug after the United States. These aspects could boost the UAE Lung Cancer Therapeutics market.

Market Restraints

Despite substantial advances in medical care, cancer quality control is still poor throughout the UAE, with major differences in cancer care across cancer facilities. Access to clinical trials is still restricted by a lack of competence and research infrastructure, as well as a tiny population, making patient recruitment for trials difficult. Instead of the existing opportunistic screening strategy, there is a need for a UAE-wide national screening programme that incorporates a call-and-recall system that covers breast, colorectal, cervical, lung, and prostate cancer. These factors may deter new entrants into the UAE Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Gulf Pharmaceutical Industries (Julphar): Gulf Pharmaceutical Industries is a UAE-based pharmaceutical company that distributes and sells a range of medicines, including those used in the treatment of lung cancer
Neopharma
SITCO
Planet Pharmacies
BinSina Pharmacy

Recent Notable Updates

January 2022: Dubai will get a new hospital that will provide cutting-edge treatments for heart and lung diseases, as well as cancer. This million-dollar project will begin in two months and is expected to take 30 months to finish. After signing an agreement at the Arab Health and Medlab Middle East Exhibition and Congress 2022, Prime Health Care Group and Dubai Health Care City have joined forces to launch the hospital in phase 2 of Dubai Health Care City. The new 100-bed hospital will treat patients with heart and lung disorders, as well as provide benchmark clinical treatment in oncology. Within the unit, advanced diagnostic and therapeutic procedures such as endobronchial ultrasound, bronchoscopy with large volume lavage, transbronchial lung biopsy, and whole lung biopsy will be available.

Healthcare Policies and Reimbursement Scenarios

The federal health authority in charge of delivering healthcare services is the Ministry of Health and Prevention. Regulations and reimbursement obligations are carried out by the Department of Health - Abu Dhabi in the Emirate of Abu Dhabi, the Dubai Health Authority (DHA) in the Emirate of Dubai, and the Sharjah Health Authority in the Emirate of Sharjah. Emirates Health Services (EHS) manages the UAE's healthcare system and provides coverage for select lung cancer medications. The Dubai Health Authority (DHA) is in charge of the city's healthcare system, and its medical insurance policies cover particular lung cancer medicines.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.